Movano Health Strengthen Board and Healthcare Investor Dr. Wirk Pursuant to FDA Clearance

PLEASANTON, California., January 2, 2025 /PRNewswire/ — The health of Movano (Nasdaq: MOVE), a health technology pioneer, today announced the expansion of its board of directors with the addition of Dr. Shaheen Wirk, a leader in dedicated healthcare funds with a track record of success medicine, collaboration and research.

With more than 20 years of investment experience in public and private health technology companies, Dr. Wirk is the founder and Chief Investment Officer of Palkon Capital Management, a dedicated healthcare startup investment firm. in partnership with Julian Robertson and Tiger Management. Previously, Dr. Wirk was a senior analyst at Bridger Capital. He is the founder of the consulting firm Blue Cotinga and was an early employee of MercuryMD, which was successfully acquired by Thomson Corp. He now serves on several boards and organizations including Tvardi Therapeutics and Duke University School of Medicine’s Medical Alumni Council, the leadership group for the Medical Alumni Association.

“It’s an exciting time for Movano to drive healthcare innovation, and they’re poised to revolutionize the delivery of healthcare data,” said Dr. Wirk. “The recent FDA approval of the EvieMED Ring allows Movano and its partners to collect important patient-specific data remotely and accurately while facilitating intensive clinical development programs and finding solutions I am proud to collaborate with Movano to achieve these goals.”

Movano Health announced last month that it had received US Food and Drug Administration (FDA) 510(k) approval for the pulse oximeter in its EvieMED Ring. The approval enables Movano Health to pursue multi-billion dollar business opportunities for health analytics solutions needed for applications such as clinical trials, post-test management, and patient monitoring. remote for health care providers and payers. The company’s first product, the Evie Ring health device, is being marketed and sold through www.eviering.com.

“We are at a critical juncture in our organization’s development as we continue to innovate at the intersection of wearables and medicine,” said John Mastrototaro, President and CEO of Movano Health. “Dr. Wirk is a visionary in the healthcare space and has extensive investment experience with private and public companies and we are pleased to have him join Movano’s Board of Directors.”

Dr. Wirk completed research training programs in oncology and trauma surgery at the University of Texas MD Anderson Cancer Center, Rabin Medical Center through Fogarty International Health Center, and Duke University Medical Center. Dr. Wirk received his MD, MBA, and BS degrees from Duke University.

About the Health of Movano
Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health is developing a portfolio of healthcare solutions aimed at bringing clinical data to the forefront of wearables. Equipped with modern and flexible data, Movano Health tools offer a new way to provide reliable data to consumers and businesses, capturing a complete picture of personal health data and uniquely translating it into personal and intellectual skills.

Movano Health’s proprietary technology and mobile medical device solutions will soon enable the use of data as a tool to monitor and manage health outcomes in the healthcare patient population. beauty. For more information about Movano Health, visit https://movanohealth.com/.

Forward-Looking Statements
This press release contains forward-looking statements about our expectations, expectations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on assumptions we have made as of this date and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding plans for the commercial launch of Evie Ring and EvieMED; our expectations regarding potential business opportunities; proposed cost reduction projects; expected FDA approval decisions regarding our products; expected future operating results; product and component development, product release, clinical trials and regulatory actions; our policies, status and expectations for future events or operations. Important factors that could cause actual results to differ materially from those in forward-looking statements are described in our most recent Annual Report on Form 10-K and any subsequent Reports. Quarterly on Form 10-Q, and in our other filings with the Securities and Exchange Commission, including under the heading “Risk Factors.” Any forward-looking statement in this release speaks only as of the date of this release. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or other.

View original media download multimedia:https://www.prnewswire.com/news-releases/movano-health-welcomes-dr-shaheen-wirk-to-its-board-of-directors-302340968.html

SOURCE Movano